Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01971346 · ClinicalTrials.gov registry record · Phase 4
The Immunological Basis for Treatment Resistance to Anti-TNF Treatments
A Phase 4 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
NCT01971346 is a Phase 4 study that has completed, run by University of Michigan. The registered enrollment target is 50 participants.
The verdict
NCT01971346, a Phase 4 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the relationship between two types of cell signals, type I interferon (IFN) and tumor necrosis factor (TNF), in psoriatic skin prior to and during treatment with etanercept and correlate that information with the degree of the improvement in the psoriasis.
Interventions
- DRUG etanercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2014-03-13 |
| Est. Completion | 2017-11-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01971346
The ClinicalTrials.gov registry entry for NCT01971346 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which etanercept is the first listed.
NCT01971346 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01971346 about?
NCT01971346 is a clinical study titled "The Immunological Basis for Treatment Resistance to Anti-TNF Treatments". The purpose of this study is to determine the relationship between two types of cell signals, type I interferon (IFN) and tumor necrosis factor (TNF), in psoriatic skin prior to and during treatment with etanercept and correlate that information with the degree of the improvement in the psoriasis.
What is the current status of trial NCT01971346?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2014-03-13. Estimated completion is 2017-11-01.
What interventions are being tested in trial NCT01971346?
The interventions under investigation include: etanercept (DRUG).
Who is sponsoring clinical trial NCT01971346?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.